BesaoT35 Tuesday, 03/17/20 10:09:26 PM Re: None Post # of 6167 Thanks Lazed. With the recent offering I think there is less than 3.5 million shares outstanding. At $1.27 NVIV market cap is around $4.2 million. The NVIV company has now $7 million in cash. The expenses are mostly paying executive salaries and bonuses. The first spinal surgery trials showed big promise but at the very end one patient died , but the death was totally unrelated to spinal surgery. The addition of nerve growth factors and/or stem cells could increase positive patient outcomes in the future. This should be a high priority area of research. To start to have an effective treatment for paralysis in humans , where in the past there was no treatment at all, should be worth something, but the stock market sees little or no value in the Neural spinal scaffold (NSS) it seems. How much more money will NVIV need to spend before completion of Inspire 2.0? Do the research medical centers bill NVIV for all the surgical costs and follow up care? Is it around 24 patients total? Thanks.